drugset / Trial / NCT00000223
Alternate-Day Buprenorphine Administration. Phase IV - 5
CrossoverDouble-blindTreatment
Summary
The purpose of this study is to determine if three times a subject's daily maintenance dose will hold for 72 hours without changes in agonist and antagonist effects.
Timeline
- Start
- 1993-06
- Primary completion
- —
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Buprenorphine | Other / unclassified | — | — |